These clinical trials include targets such as IRAK4 in DLBCL, BTK in B-cell malignancies, IKZF1/3 in MM and CML, and GSPT1 in AML [248]. Likewise, BRD9, a key component of the ncBAF complex, has been proposed as a therapeutic target in a group of leukemias. Here, BRD9 is linked to Miyoshi myopathy.